Recent developments have shown the potential for the use of AI in the early detection of diseases such as cancer, Alzheimer's and retinal diseases. What is the current state of this technology? What will this mean for clinicians and patients? What are the ethical implications? How do we regulate this rapidly evolving technology? These are just some of the questions that we hope to explore at this discussion event.
This discussion appeared in the FST journal below.